Suppr超能文献

放疗治疗侵袭性纤维瘤病:单中心经验。

Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution.

机构信息

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.

出版信息

Radiat Oncol. 2020 Jun 5;15(1):143. doi: 10.1186/s13014-020-01565-9.

Abstract

BACKGROUND

Desmoid-type fibromatosis is a rare, potentially locally aggressive disease. Herein we present our experience in the treatment with radiotherapy.

METHODS AND MATERIALS

In total 40 patients who received 44 treatments from 2009 to 2018 at the Heidelberg University Hospital with photons (N = 28) as well as protons (N = 15) and carbon ions (N = 1) were investigated. The median age at radiotherapy was 41 years [range 8-78]. Familial adenomatous polyposis (FAP) was confirmed for nine patients and 30 had a unifocal desmoid tumor. The localizations were abdominal wall, abdominopelvic cavity, thoracic wall, extremity, head and neck and trunk. The median prescribed dose was 54 Gy/ Gy (RBE) [range 39.6-66, IQR 50-60]. Eleven treatments were performed at the time of first diagnosis; 33 at the time of progression or recurrence. Post-operative radiotherapy was performed in 17 cases. The median planning target volume was 967 ml [84-4364 ml, IQR 447-1988]. Survival analysis was performed by the Kaplan-Meier Method.

RESULTS

The median follow-up time was 32 months [1-153]. At the end of the follow-up interval all patients but one were alive. The estimated local progression free survival of the treated lesion in 3 and 5 years was 76.4% and 63,8%, respectively. The progression-free survival in 3 and 5 years was 72.3 and 58.4% and the overall survival was 97.4 and 97.4%, respectively. In case of macroscopic tumor (N = 31) before radiotherapy a partial remission was observed in 12 cases (38.7%) and a complete remission in 4 cases (12.9%). Progression was observed in 13 (29.5%) cases, predominantly at the margin of the planning target volume (PTV, N = 5, 38,4%) followed by progression within the PTV (N = 4, 30.8%). In univariate analysis multifocal localization was associated with impaired progression-free survival (p = 0.013). One patient developed a grade V gastrointestinal bleeding, otherwise no acute toxicity >°III was observed. Late toxicity was depending on the localization of the desmoid tumor and was especially severe in patients with FAP and abdominopelvine desmoids including gastrointesinal fistula, perforation and abscess.

CONCLUSION

Radiotherapy in the treatment of desmoids can lead to long term control. Treatment of patients with abdominopelvine desmoids should be avoided, as the risk of higher-grade complications is substantial.

摘要

背景

韧带样纤维瘤病是一种罕见的、潜在局部侵袭性疾病。在此,我们报告我们在放疗治疗方面的经验。

方法和材料

共有 40 名患者于 2009 年至 2018 年在海德堡大学医院接受治疗,其中 28 名患者接受光子放疗,15 名患者接受质子放疗,1 名患者接受碳离子放疗。放疗时的中位年龄为 41 岁[年龄范围 8-78 岁]。9 名患者被确诊为家族性腺瘤性息肉病(FAP),30 名患者为单发韧带样纤维瘤。病变部位包括腹壁、腹盆腔、胸壁、四肢、头颈部和躯干。中位处方剂量为 54 Gy/ Gy(RBE)[剂量范围 39.6-66 Gy,IQR 50-60 Gy]。11 次治疗在首次诊断时进行;33 次在进展或复发时进行。17 例患者在手术后进行了放疗。中位计划靶区体积为 967 ml[84-4364 ml,IQR 447-1988 ml]。采用 Kaplan-Meier 法进行生存分析。

结果

中位随访时间为 32 个月[1-153 个月]。随访结束时,除 1 例患者外,所有患者均存活。治疗后 3 年和 5 年的局部无进展生存率分别为 76.4%和 63.8%。3 年和 5 年的无进展生存率分别为 72.3%和 58.4%,总生存率均为 97.4%。在放疗前有肉眼肿瘤(N=31)的情况下,12 例(38.7%)观察到部分缓解,4 例(12.9%)观察到完全缓解。13 例(29.5%)出现进展,主要发生在计划靶区(PTV)边缘(N=5,38.4%),其次是 PTV 内进展(N=4,30.8%)。单因素分析显示,多发病灶与无进展生存不良相关(p=0.013)。1 例患者发生 5 级胃肠道出血,无其他急性毒性>°III 级。晚期毒性取决于韧带样纤维瘤的位置,尤其是在 FAP 和腹盆腔韧带样纤维瘤患者中,包括胃肠道瘘、穿孔和脓肿,其毒性更为严重。

结论

放疗治疗韧带样纤维瘤可以长期控制疾病。应避免治疗腹盆腔韧带样纤维瘤,因为发生更高等级并发症的风险很大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57bd/7275436/dd74f61195df/13014_2020_1565_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验